An Exploratory Case-Control Study of Genetic and Clinical Factors For Serious Cutaneous Reactions Among Users of Eslicarbazepine Acetate With New Medications taken for atleast 3 months prior to the study

An Exploratory Case-Control Study of Genetic and Clinical Factors For Serious Cutaneous Reactions Among Users of Eslicarbazepine Acetate With New Medications taken for atleast 3 months prior to the study
Recruiting
1 years - 100 years
Non-Binary
Phase N/A
2 Locations

Brief description of study

Eslicarbazepine acetate (Aptiom®) is an antiepileptic drug (AED) approved in the United States (US) as adjunctive therapy for the treatment of partial-onset seizures in adults .Prior research has shown that seizure medicines like carbamazepine (Tegretol®) and oxcarbazepine (Trileptal®, Oxtellar®) are more likely to cause severe drug related skin reactions in some people of Asian ancestry who have specific genes. These are genes found in an area of your chromosomes (packaging for your genes) called the Major Histocompatibility Complex. This association is called a genetic risk factor.

Detailed description of study

We plan to compare information that we obtained from participants who take Aptiom® and have not experienced a severe skin reaction to a group of patients who also have a history of seizure disorders and do have a history of a severe skin reaction after using Aptiom®. We will ask participants for a sample of their Deoxyribonucleic Acid (DNA). This sample can be obtained from saliva (spit). We will ask for information about skin reactions and medications. We plan to enroll about 500 individuals with a history of seizures who used Aptiom® and who did not have a severe skin reaction, and 25 participants who have used Aptiom® and experienced a severe skin reaction.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Epilepsy
  • Age: 1 years - 100 years
  • Gender: Non-Binary
Updated on 22 Jan 2025. Study ID: TX1066

Find a site

Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Message For Non Enrolling By Invitation Trial

Select a study center that’s convenient for you, and get in touch with the study team.